Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

Tracy Staton

When announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a war? If had to boost its rebates to win coverage–which the company admits it did–then that means its rivals, including Eli and Nordisk, have, too.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS